文献速递中枢神经肿瘤放疗放疗物理与技术

新诊断胶质母细胞瘤标准放疗与5次自适应立体定向放疗的倾向评分匹配比较

Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score-Matched Analysis.
PubMed 文献 · Adv Radiat Oncol · 2025-05-18

该回顾性研究纳入96例新诊断胶质母细胞瘤成人患者,经倾向评分匹配比较5次、15次和30次分组的生存结局。匹配后5次与15次(14对)及5次与30次(17对)分组的中位总生存期、无进展生存期、局部失败和3级毒性均无显著差异,5次组中位旅行距离更低。

要点

  • 匹配后5次与15次、5次与30次分组的中位总生存期和无进展生存期均无显著差异。
  • 局部失败率和3级毒性率在各分组间相似。
  • 5次组中位旅行距离为220英里,低于15次组的877.5英里和30次组的1638英里。

核心结论

  • 自适应5次放疗与常规分割放疗相比显示出可比的生存结局,同时减少了治疗相关的旅行负担。
  • 需要进一步的前瞻性研究来验证其在胶质母细胞瘤管理中的作用。

研究设计与样本

  • 回顾性研究纳入2018至2024年间在该机构治疗的96例新诊断胶质母细胞瘤成人患者。
  • 纳入标准包括年龄18岁、确诊胶质母细胞瘤并完成治疗,排除既往脑部放疗或治疗不完整者。
  • 采用倾向评分匹配平衡5次、15次和30次分组的人口学、肿瘤特征和治疗方案。
  • 匹配后5次与30次分组为17对,5次与15次分组为14对。
  • 统计分析包括Fisher精确检验、Mann-Whitney U检验、Cox比例风险模型和Kaplan-Meier生存曲线。

主要发现

  • 中位总生存期:5次组21.1个月 vs 15次组18.2个月(P = .77);5次组11.7个月 vs 30次组14.6个月(P = .5)。
  • 中位无进展生存期:5次组9.0个月 vs 15次组7.9个月(P = .89);5次组8.9个月 vs 30次组9.7个月(P = .97)。
  • 局部失败和3级毒性率在各分组间相似。
  • O6-甲基鸟嘌呤-DNA甲基转移酶未甲基化状态、较高的东部肿瘤协作组评分和年龄60岁与更差的无进展生存期和总生存期相关。
  • 5次组中位旅行距离为220英里,15次组为877.5英里,30次组为1638英里。

临床怎么用

  • 对于新诊断胶质母细胞瘤且适合常规分割的患者,自适应5次立体定向放疗可作为减少治疗负担的候选方案。
  • 治疗决策时需考虑O6-甲基鸟嘌呤-DNA甲基转移酶未甲基化状态、东部肿瘤协作组评分和年龄60岁等预后因素。
  • 自适应放疗的实时肿瘤监测体积变化尚未显示与临床结局相关,不应作为疗效判断依据。

局限性

  • 本研究为单中心回顾性分析,样本量有限。
  • 倾向评分匹配后每组配对数量较少(5次与30次17对,5次与15次14对)。
  • 需要前瞻性研究验证自适应5次放疗在胶质母细胞瘤管理中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, with poor survival despite advancements in treatment. Adaptive stereotactic radiation therapy (RT) using a magnetic resonance imaging linear accelerator is an emerging approach for patients with newly diagnosed GBM eligible for conventional fractionation. We hypothesize that adaptive stereotactic RT can provide comparable outcomes with conventional fractionation while reducing treatment burden. METHODS AND MATERIALS: We retrospectively reviewed 96 adults with newly diagnosed GBM treated at our institution between 2018 and 2024. Inclusion criteria included the age of 18 years, confirmed GBM diagnosis, and completed treatment. Patients with prior brain irradiation or incomplete treatment were excluded. Propensity score matching was performed to balance demographics, tumor characteristics, and treatment protocols across 5-fraction, 15-fraction, and 30-fraction groups. Statistical analyses included the Fisher exact test, Mann-Whitney U test, Cox proportional hazards models, and Kaplan-Meier survival curves. RESULTS: After propensity score matching, 17 pairs were matched for 5 versus 30 fractions and 14 pairs for 5 versus 15 fractions. Median overall survival was 21.1 versus 18.2 months (5 vs 15 fractions, P = .77) and 11.7 versus 14.6 months (5 vs 30 fractions, P = .5). Median progression-free survival was 9.0 versus 7.9 months (5 vs 15 fractions, P = .89) and 8.9 versus 9.7 months (5 vs 30 fractions, P = .97). Local failure and grade 3 toxicity rates were similar across groups. O6-methylguanine-DNA-methyltransferase unmethylated status, higher Eastern Cooperative Oncology Group scores, and age 60 years were associated with worse progression-free survival and overall survival. Median travel distances were lower in the 5-fraction group, with a median of 220 miles compared with 877.5 (15 fractions) and 1638 miles (30 fractions). Adaptive RT allowed for real-time tumor monitoring but volumetric changes did not correlate with clinical outcomes. CONCLUSIONS: Adaptive 5-fraction RT demonstrates comparable survival outcomes with conventional fractionation while reducing treatment-related travel burden. Further prospective studies are needed to validate its role in GBM management.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dohopolski M, Schmitt LG, de Vis J, et al. Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score-Matched Analysis. Adv Radiat Oncol. 2025. PMID: 40611877. doi:10.1016/j.adro.2025.101813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。